A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer
← catalyst calendarNCT04486378 · readout ≤ 103 d
Sponsored by BioNTech SE (industry) · BNTX — their whole pipeline →. With Genentech, Inc..
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
327estimated
Sites
86
Countries
Belgium, Canada, Germany +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-03-08 | actual | When the study began enrolling |
| Primary completion | Nov 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Aug 2030 | estimated | The whole study's end, after follow-up |
| First posted | 2020-07-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Colorectal Cancer Stage II
- Colorectal Cancer Stage III
Interventions
- Drug: RO7198457 intravenous (IV)
- Other: Observational group (no intervention)
Primary outcome
what the primary-completion date above is the date OFDisease-free survival (DFS)
measured Through study completion, up to 5 years
Permalink · BNTX's whole pipeline · Catalyst calendar · Every registered study · What changed